We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FTC will conduct a study on the competitive effects of authorized generics, the latest in a string of actions that shows the commission is taking a harder line on potentially anticompetitive agreements between drugmakers.
A national push to increase the transparency of financial dealings between drugmakers and pharmaceutical benefit managers (PBMs) has suffered numerous setbacks in state legislatures this year, but proponents argue that upcoming legal battles could turn the tide.
Express Scripts has doubled the number of generic drugs it offers through a program to provide generic drugs to low-income patients at discounted prices.
Higher copayments and drug-safety concerns have contributed to a slowdown in prescription drug spending, according to a new report published in the journal Health Affairs.
Prescription drug sales in the U.S. rose 5.4 percent to $251.8 billion in 2005, due to strong growth in biotech and generic drug sales, according to pharmaceutical industry research firm IMS Health.
Drug-safety concerns and higher copayments have contributed to a slowdown in prescription drug spending, according to a new report published in the journal Health Affairs.
U.S. prescription drug sales rose 5.4 percent to $251.8 billion in 2005, due to strong growth in biotech and generic drug sales, according to pharmaceutical industry research firm IMS Health.
Every $10 difference between brand and generic copayments can increase the generic substitution rate by 3 to 4 percent, according to a study by pharmacy benefit manager Express Scripts.